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Abstract
Phosphatidylcholine transfer protein (PC-TP, synonym StARD2) is a highly specific intracellular
lipid binding protein that is enriched in liver. Coding region polymorphisms in both humans and
mice appear to confer protection against measures of insulin resistance. The current study was
designed to test the hypotheses that Pctp−/− mice are protected against diet-induced increases in
hepatic glucose production and that small molecule inhibition of PC-TP recapitulates this
phenotype. Pctp−/− and wild type mice were subjected to high fat feeding, and rates of hepatic
glucose production and glucose clearance were quantified by hyperinsulinemic euglycemic clamp
studies and pyruvate tolerance tests. These studies revealed that high fat diet-induced increases in
hepatic glucose production were markedly attenuated in Pctp−/− mice. Small molecule inhibitors
of PC-TP were synthesized and their potencies, as well as mechanism of inhibition, were
characterized in vitro. An optimized inhibitor was administered to high fat fed mice and used to
explore effects on insulin signaling in cell culture systems. Small molecule inhibitors bound PC-
TP, displaced phosphatidylcholines from the lipid binding site and increased the thermal stability
of the protein. Administration of the optimized inhibitor to wild type mice attenuated hepatic
glucose production associated with high fat feeding, but had no activity in Pctp−/− mice.
Indicative of a mechanism for reducing glucose intolerance that is distinct from commonly utilized
insulin-sensitizing agents, the inhibitor promoted insulin-independent phosphorylation of key
insulin signaling molecules. These findings suggest PC-TP inhibition as a novel therapeutic
strategy in the management of hepatic insulin resistance.
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Phosphatidylcholine transfer protein (PC-TP) is a soluble highly specific lipid binding
protein with accentuated expression in the liver (1). PC-TP was identified, purified and
named based on its capacity to catalyze the intermembrane exchange of
phosphatidylcholines in vitro (2). According to its characteristic lipid binding pocket that
accommodates a single phosphatidylcholine molecule (3), PC-TP has been designated
StARD2 within the steroidogenic acute regulatory protein–related transfer (START) domain
superfamily (3, 4). Specificity for binding phosphatidylcholines is conferred by a uniquely
structured phosphorylcholine head group binding site within the lipid binding pocket of PC-
TP (3). Interestingly, evidence for a biological role for PC-TP in lipid transport in vivo is
generally lacking (5), and we have instead reported the unanticipated finding that PC-TP
regulates glucose metabolism (6): Livers of chow fed Pctp−/− mice exhibit increased insulin
sensitivity, as evidenced by profound decreases in hepatic glucose production under
hyperinsulinemic euglycemic clamp conditions (6). Although the molecular mechanism is
not fully understood, PC-TP may control hepatic glucose homeostasis in response to
variations in the fatty acyl composition of membrane phospholipids (5).
Type 2 diabetes is characterized by excess hepatic glucose production due to insulin
resistance, commonly in the setting of obesity (7). As evidenced by coding region
polymorphisms in both humans and mice, PC-TP may play a pathogenic role. A Glu10Ala
substitution in human subjects in the Quebec Family Study was correlated with a three-fold
lower risk of the atherogenic small dense LDL phenotype (8), which is commonly
associated with insulin resistance (9). In New Zealand Obese (NZO) mice, an Arg120His
substitution in PC-TP appeared to play a protective role against the development of obesity-
associated type 2 diabetes (5, 10). The current study was designed to provide a direct test of
whether Pctp−/− mice are resistant to high fat diet-induced increases in hepatic glucose
metabolism and whether small molecule inhibition of PC-TP would recapitulate this
phenotype.
Materials and Methods
Mice, diet and treatments
Pctp−/− and wild type control mice 7 generations backcrossed into FVB/NJ genetic
background (11) were housed in a standard 12 h alternate light/dark cycle facility, and fed a
standard rodent diet 5001 (LabDiets, St. Louis, MO) with free access to drinking water.
Protocols for animal use and euthanasia were approved by the institutional committees of
the Harvard Medical School and the Albert Einstein College of Medicine. Experiments were
conducted using male mice. Starting at 4 – 5 w of age, mice were fed a high fat diet (60 %
kcal; D12492; Research Diets, New Brunswick, NJ) for periods ranging from 8 to 18 w prior
to commencing experiments. Mice were weighed weekly and rates of food consumption
were calculated per mouse from the weight of food withdrawn by all of the mice in the cage
each week. Prior to selected experiments, mice were anesthetized by i.p. injection of
ketamine (87 mg/kg b.w.) plus xylazine (13 mg/kg b.w.) (Webster Veterinary, Sterling,
MA). In experiments designed to test the influence of PC-TP inhibition on glucose
homeostasis, administration of compound A1 (see Supporting Information - Materials and
Methods for synthesis and assays of microsomal stability and pharmacokinetics) or vehicle
was initiated concurrently with the high fat diet. Compound A1 was prepared to a final
concentration of 0.6 mg/ml in 4% DMSO and 96% of 6% hydroxypropyl-β-cyclodextrin
(Sigma Aldrich, St. Louis, MO) solution in sterile water. Mice were injected i.p. 5 d per w
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with 3 mg/kg compound A1 or the equivalent volume of vehicle (5 µl/g). For all
experiments, mice were sacrificed after an overnight fast.
Analytical techniques
Plasma non-esterified fatty acids (NEFA), triglyceride, cholesterol and phospholipid
concentrations were determined using reagent kits from Wako (Richmond, VA), Sigma
Aldrich and Roche Diagnostics (Indianapolis, IN), respectively. Blood glucose was
determined using a OneTouch Ultra glucose monitor (LifeScan, Milpitas, CA). Hepatic
concentrations of triglycerides and cholesterol were measured enzymatically following
hepatic lipid extraction (12). Plasma insulin, leptin and adiponectin were determined by
ELISA as a service of the Joslin Diabetes and Endocrinology Research Center Specialized
Assay Core (NIH 5P30 DK36836, Joslin Diabetes Center, Boston, MA). Plasma activities of
alanine aminotransferase (ALT) and concentrations of bilirubin were determined using
standard assays by Charles River Research Animal Diagnostic Services (Wilmington, MA).
To assess protein expression, liver tissue or cell lysates were homogenized in RIPA buffer
supplemented with protease and phosphatase inhibitors (Roche Diagnostics). Lysates were
rotated slowly at 4 °C for 30 min and then centrifuged at 12,000 × g for 10 min to remove
cellular debris. Proteins were fractionated by SDS-PAGE and subjected to immunoblot
analysis. An anti-PC-TP rabbit polyclonal antibody was as described (13). Antibodies
against pAkt(S473)/total Akt, pS6K(T389)/total S6K, pGSK3β(S9), pAMPK(T172)/total
AMPK were from Cell Signaling Technology (Beverly, MA). An antibody against total
GSK3β was from BD Transduction Laboratories (Woburn, MA), and an antibody against β-
actin was from Sigma Aldrich. Detection was by enhanced chemiluminescence using a
Western Lightning chemiluminescence reagent (PerkinElmer, Waltham, MA). For histologic
analysis, sections of liver were fixed in 10% formalin. Samples were processed, sectioned
and stained for hematoxylin and eosin as a service of the Dana-Farber/Harvard Cancer
Center Rodent Histopathology Core (supported in part by an NCI Cancer Center Support
Grant NIH 5P30 CA06516).
Magnetic resonance imaging of body fat
Images of mice were acquired with a GE/Omega 9.4 Tesla vertical wide-bore spectrometer
operating at a 1H frequency of 400 MHz and equipped with 50-mm shielded gradients
(General Electric, Fremont, CA) and a 40-mm 1H imaging coil (RF Sensors, New York,
NY). The following parameters were used to obtain transverse and sagittal images: echo
time, 30 msec; field of view, 51.2 mm; number of averages, 2; slice thickness, 3 mm; gap
0.5 mm, repetition time, 0.4 sec; matrix size, 128 × 256 (interpolated to 256 × 256). Water
images were acquired with the water peak on resonance, fat images were acquired with the
lipid CH2 peak on resonance (14). Imaging data were analyzed using MATLAB-based
software (The MathWorks, Natick, MA). Spectroscopy studies were conducted prior to
imaging using the same coil and a routine pulse-acquire sequence (4 signal averages, 5 sec
delay between scans). The areas under the fat and water peaks were integrated using the
spectrometer software and were used to calculate the %fat/water and %fat mass.
Pyruvate and glucose tolerance tests
Pyruvate and glucose tolerance tests were performed after an overnight fast (15–17). Plasma
glucose was measured at baseline. This was followed by i.p. injection of 2 mg/g b.w. of
sodium pyruvate (0.4 g/ml in sterile PBS) for pyruvate tolerance tests or 1 mg/g b.w. D-
glucose (20% wt/vol) for glucose tolerance tests. Blood glucose concentrations were
measured periodically for up to 180 min. For experiments in which both were performed,
mice were allowed to recover for 1 w in between pyruvate and glucose tolerance tests.
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Hyperinsulinemic euglycemic clamp studies
Studies were performed in conscious, unrestrained mice fitted with intravenous catheters
(18). Briefly, food was removed 5 h prior to commencing the studies, and infusions lasted
for 90 min. Mice received a constant infusion of HPLC purified insulin (3.6 mU/min/kg
b.w.) and [3H-3]-glucose (0.1 µCi/min; PerkinElmer). A glucose solution (10% wt/vol) was
infused at a variable rate so that plasma glucose concentration was constant at 8 mM
throughout the experiment. Plasma glucose concentrations and specific activities were used
to determine rates of glucose uptake and hepatic glucose production (6).
Structure-activity relationships of small molecule inhibitors and mechanism of PC-TP
inhibition
As described in Supporting Information - Materials and Methods, recombinant PC-TP,
StARD7 and StARD10 were purified, and small molecule inhibitors were synthesized and
used in assays of phosphatidylcholine transfer activity, PC-TP-inhibitor binding by surface
plasmon resonance, displacement of pyrene-labeled phosphatidylcholine (Pyr-PC), thermal
stability using ThermoFluor and PPARγ activation.
Phosphorylation of signaling proteins in cultured cells
Frozen primary human hepatocytes (CellzDirect/Invitrogen, Carlsbad, CA) were thawed
using cryopreserved hepatocyte recovery medium, then plated in serum containing plating
media for 6 h to allow cells to adhere. After overnight starvation in serum free medium,
compounds A1 or B1 dissolved in DMSO was added (0.1% final concentration of DMSO)
for 60 min. Negative controls included no addition and 0.1% DMSO. The positive control
included 0.1% DMSO plus insulin (50 nM) for 30 min. Compound A1 was also tested in
human embryonic kidney (HEK) 293E cells (19). HEK 293E were maintained in DMEM
supplemented with 10% fetal calf serum and 1% penicillin-streptomycin and then starved
overnight. Cells were then exposed to compound A1 for 60 min.
Statistics
Data are reported as means ± SEM. Differences between groups were analyzed using a two-
tailed unpaired Student’s t-test.
Results
Attenuation of diet-induced hepatic glucose production in high fat fed Pctp−/− mice
In mice fed a high fat diet, the lack of PC-TP expression did not influence growth or food
consumption (Supporting Fig. 1A) and obesity was evidenced by body weights that
exceeded chow fed counterparts (6) by up to 40%. After 8 w, fasting plasma glucose
concentrations (Fig. 1A) were similar to those previously reported for chow fed mice (6) and
were similarly decreased in Pctp−/− mice. The high fat diet for 12 w was sufficient in wild
type mice to elevate plasma glucose concentrations, which did not rise in Pctp−/− mice until
18 w. As a result, the absence of PC-TP expression was associated with 25%, 46%, and 17%
reductions in fasting plasma glucose concentrations at 8, 12, and 18 w of high fat feeding,
respectively. Hyperinsulinemic euglycemic clamp studies performed after 18 w revealed a
3.6 fold increase in glucose infusion rate in Pctp−/− mice (Fig. 1B). Whereas the rate of
glucose uptake was unchanged, hepatic glucose production was decreased by 46%. In order
validate an alternative, more facile procedure to determine rates of hepatic glucose
production, mice fed the high fat diet for 12 w were subjected to pyruvate tolerance tests
(16). Reduced plasma glucose concentrations were observed in Pctp−/− mice during the
course of the pyruvate tolerance tests (Fig. 1C), such that the mean values for area under the
curve (AUC) were reduced 32% compared with wild type mice.
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Percentages of body fat, as well as other metrics of body and plasma compositions were
measured after 12 w on the high fat diet. In contrast to our previous findings (6), the
percentages of body fat in high fat fed mice did not differ between the two genotypes (inset
to Supporting Fig. 1A). Moreover, liver and epididymal fat pad weights were similar (Table
1) and both macro- and micro-vesicular hepatic steatosis were equally present (Supporting
Fig. 2). High fat fed Pctp−/− mice did not exhibit changes in leptin or adiponectin
concentrations or in plasma or hepatic concentrations of insulin, NEFA, triglycerides,
cholesterol and phospholipids (Table 1).
Identification of an optimized small molecule inhibitor of PC-TP
In a high-throughput screening of 114,752 compounds, we previously identified 6 distinct
small molecule inhibitors of the phosphatidylcholine transfer activity of PC-TP (20). To
select an optimized molecule for a therapeutic trial in mice, we synthesized structural
analogs around the two most potent inhibitors identified in the screen, A1 and B1 (Fig. 2).
Structure-activity analyses using a fluorescence quench assay (Supporting Fig. 3) revealed
molecular features that influence the IC50 values (Fig. 2). For the A series, at least one
halogen group on the terminal ring at R1 was essential for inhibition. The addition of a
methyl substituent to the aryl amide at R3 reduced inhibition more than 30-fold. Finally, the
two methyl substituents at R5 were essential for inhibitory activity. For the B series,
essential features for inhibition included a sulfur atom at position X, a Ph on the α-carbon of
the amide at R2, as well as the nature of substituents on the terminal ring, particularly 2,3-
dichloro at R4. Additionally, the introduction of methyl on the amide nitrogen at R3
eliminated inhibition. StARD10 activity was inhibited by selected compounds, but less
effectively (Supporting Fig. 3B), with the IC50 values (Fig. 2) ranging from 1.5 – 10 fold
greater than for PC-TP. StARD7 was only modestly inhibited by compounds A1 and B1
(IC50 ~70 µM) and more weakly inhibited by other compounds at higher IC50 values that
could not be quantified under conditions of the assay.
Compound A1 binds PC-TP, displaces phosphatidylcholine and increases thermal stability
We used surface plasmon resonance to demonstrate binding of representative inhibitors
directly to PC-TP with KD values in the micromolar range (Fig. 3A). Compound A10, which
demonstrated no inhibitory activity (Fig. 2) did not bind PC-TP. Because the parent
compounds from each series (i.e. A1 and B1) exhibited both the lowest IC50 values and
greatest specificity for PC-TP, these were tested for in vitro microsomal stability in order to
determine their potential utilities in vivo. This revealed a 6.5-fold greater metabolic stability
of compound A1 (compound A1, half-life (t1/2) = 230 min and intrinsic clearance (Clint) =
6.0 µL/min/mg protein; compound B1, t½ = 35.6 min and Clint = 39 µL/min/mg protein).
Based on this result, we selected compound A1 (LDN-193188) for additional
characterization. In a fluorescence competition assay, compound A1 displaced a fluorescent
phosphatidylcholine from the lipid binding pocket of PC-TP (Fig. 3B). The Krel value for
compound A1 was 20% of the Krel for phosphatidylcholine (inset to Fig. 3B). Finally, we
demonstrated that compound A1 increased the thermal stability of PC-TP (Fig. 3C): The Tm
of PC-TP, which was markedly increased when PC-TP was bound by phosphatidylcholine,
was further increased when bound by compound A1 (inset to Fig. 3C).
Compound A1 attenuates diet-induced hepatic glucose production in wild type mice
Based upon a pharmacokinetic analysis, which revealed a maximum plasma concentration
(Cmax) = 54 µM, time to maximum concentration (tmax) = 0.5 h and t1/2 = 19.4 h following a
single 3 mg/kg i.p. dose of compound A1, we designed a dosing schedule in which 3 mg/kg
of inhibitor or the equivalent volume of vehicle was administered i.p. daily for 5 d per w for
12 w. Mice administered the inhibitor exhibited similar weight gain and food consumption
as vehicle-treated mice (Supporting Figs. 1B and 1C), although neither group gained as
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much weight as high fat fed mice that were not subjected to i.p. injection (Supporting Fig.
1A).
Treatment with compound A1 led to a 31% reduction in fasting plasma glucose
concentrations (mg/dl) in wild type mice, but did not significantly affect Pctp−/− mice
(Table 1). The inhibitor improved glucose tolerance tests for wild type mice (Fig. 4A), as
evidenced by separation of the response curves and a 20% reduction in AUC compared with
vehicle-treated controls. Pctp−/− mice did not respond to inhibitor treatment (Fig. 4B).
Consistent with decreased hepatic glucose production, compound A1 also improved the
pyruvate tolerance tests of wild type but not Pctp−/− mice (Figs. 4C and D), with separation
of response curves and a 20% reduction in AUC for wild type mice, which did not achieve
statistical significance. For both glucose and pyruvate tolerance tests, the similar peak
glucose concentrations and AUC values in wild type mice treated with compound A1 and in
Pctp−/− mice treated with either compound A1 or vehicle suggests that PC-TP was
completely inhibited by compound A1.
Treatment of mice with compound A1 did not alter plasma concentrations of insulin or
NEFA (Table 1). Although body composition was not measured directly in these mice, there
were no changes in epididymal fat pad weights or plasma concentrations of leptin and
adiponectin. In livers of wild type mice treated with compound A1, we observed increases in
triglyceride and cholesterol concentrations together with non-significant increases in plasma
triglyceride and cholesterol concentrations. Livers of mice treated with either compound A1
or vehicle exhibited microvesicular steatosis, but did not show histologic evidence of
toxicity or inflammation (Supporting Fig. 2). Treatment with compound A1 was not
associated with ALT elevations (Supporting Fig. 4A), and plasma bilirubin concentrations
tended to decline in both genotypes (Supporting Fig. 4B).
Compound A1 activates insulin signaling
Fig. 5A shows insulin-independent increases in the phosphorylation of Akt, p70 ribosomal
S6 kinase (S6K) and glycogen synthase kinase 3β (GSK3β) following exposure of cultured
primary human hepatocytes or HEK 293E cells to concentrations of compound A1 achieved
in vivo. This suggested that compound A1 augments the intrinsic cellular response to insulin
signaling due to specific inhibition of PC-TP. Similar effects of compound B1 in primary
human hepatocytes (Supporting Fig. 5A) support this assertion, as does increased basal
phosphorylation of Akt and S6K in livers of fasted wild type but not Pctp−/− mice treated
with compound A1 (Fig. 5B and Supporting Fig. 5B). The absence of changes in PC-TP
expression in cultured cells or in livers of inhibitor treated wild type mice (Fig. 5A and
Supporting Fig. 5) indicates that small molecule inhibition does not reduce PC-TP
expression or accelerate its degradation. Finally, we tested compounds A1 and B1 for
activation of PPARγ (Supporting Fig. 6), but neither compound exhibited this activity.
Discussion
Our interest in PC-TP as a therapeutic target was motivated by the unexpected initial finding
of increased hepatic insulin sensitivity in chow fed Pctp−/− mice (6). These mice exhibited
reduced fasting plasma glucose concentrations and profound decreases in hepatic glucose
production under conditions of a hyperinsulinemic-euglycemic clamp. In addition to
increased Akt phosphorylation in cultured primary hepatocytes that lacked PC-TP
expression, an increased percentage of body fat in Pctp−/− mice was associated elevated
plasma concentrations of both leptin and adiponectin. These findings suggested two
potential mechanisms for increased hepatic insulin sensitivity; intrinsic sensitization of
hepatocytes to insulin and adipokine-mediated sensitization of the liver to insulin action.
The current study confirms and extends our observations in chow fed mice by demonstrating
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that Pctp−/− mice are resistant to diet-induced glucose intolerance, but not to obesity. The
high fat diet eliminated genotype-dependent differences in body composition and
adipokines, as well as plasma and hepatic concentrations of NEFA, triglycerides and
cholesterol. Therefore, the persistent decrease in hepatic glucose production was most likely
attributable to intrinsic sensitivity of the liver to insulin action in the absence of PC-TP
expression. When taken together with genetic evidence that PC-TP polymorphisms are
protective against insulin resistance in humans (8) and mice (10), these findings prompted us
to examine whether pharmacological inhibition of PC-TP would recapitulate the same
effects and serve as proof-of-concept for a novel therapeutic modality.
In order to identify an optimized small molecule inhibitor for a therapeutic trial in mice, we
subjected the two most potent compounds identified in a small molecule screen (20) to
systematic structure-function analyses. These identified molecular features required for
inhibition, but did not ultimately generate compounds with in vitro potencies beyond those
observed for the parent molecules (i.e. compounds A1 and B1). To further characterize the
inhibitors, we tested their specificity against other mammalian proteins that exhibit
phosphatidylcholine transfer activity in vitro (5). We selected two closely related START
domain proteins (21). StARD10 is overexpressed in some primary human breast cancers
(22), and like PC-TP, it binds and transfers phosphatidylcholines in vitro (23). StARD10
activity was inhibited by compound A1, but less effectively. StARD7 is a highly expressed
protein in a choriocarcinoma cell line (24) and exhibits phosphatidylcholine transfer activity
(25). It was only modestly inhibited by compounds A1 and B1, although precise IC50 values
for these weakly active compounds could not be quantified under conditions of the assay.
These findings suggest that small molecule inhibition was at least relatively selective for the
structural characteristics of PC-TP.
An important unresolved question from the initial high-throughput screen (20) was the
mechanism of inhibition. The in vitro activity of PC-TP in the fluorescence quench assay
reflects a multistep process (20): The protein must first associate with a donor small
unilamellar vesicle, exchange a phosphatidylcholine molecule, dissociate from the vesicle,
associate with an acceptor small unilamellar vesicle, again exchange a phosphatidylcholine
and then dissociate. Therefore, it was possible that the small molecule inhibitors might not
bind directly to PC-TP, but may have instead inserted into the membrane bilayer and
disrupted membrane association of the protein. Because such a mechanism would likely
reduce the therapeutic potential of an inhibitor in vivo, we explored whether the compounds
bound directly to PC-TP. Surface plasmon resonance, which is a sensitive biophysical
technique for the measurement of ligand protein interactions (26), revealed that inhibitors of
PC-TP bound the protein with KD values that were in good agreement with respective IC50
values. In further support of an inhibitory mechanism that involved direct binding to the
protein, compound A1 displaced a fluorescent phosphatidylcholine analog from the PC-TP
lipid binding pocket, displaying similar relative affinity for PC-TP as natural
phosphatidylcholines. Compound A1 also increased the thermal stability of PC-TP,
providing additional independent evidence for inhibitor-protein binding.
Because of its favorable metabolic and pharmacokinetic characteristics, we selected
compound A1 for in vivo testing. Consistent with a PC-TP-dependent mechanism of glucose
regulation, the administration of this compound to high fat fed mice led to significant
reductions in fasting plasma glucose concentrations and improved glucose tolerance tests for
wild type, but not Pctp−/− mice. Due to prohibitive logistical issues, we were unable to
perform hyperinsulinemic euglycemic clamp studies to determine whether inhibitor
treatment reduced hepatic glucose production. We therefore used pyruvate tolerance tests as
a more facile surrogate measure of hepatic glucose production. In a pyruvate tolerance test,
the gluconeogenic substrate pyruvate is converted to glucose by the liver and exported into
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plasma (16). Having validated this approach against hyperinsulinemic euglycemic clamp
studies using untreated high fat fed mice, pyruvate tolerance tests were utilized to
demonstrate a PC-TP-dependent reduction in hepatic glucose production by compound A1.
Inhibitor treatment of wild type mice was not associated with differences in plasma
concentrations NEFA, leptin and adiponectin, or in other lipid-related parameters that might
influence insulin sensitivity (27). These findings suggested that inhibitor-mediated
improvements in glucose homeostasis were attributable to the activity of compound A1 in
the liver. This possibility was tested in primary human hepatocytes and HEK 293 cells, both
of which exhibited robust expression of PC-TP. Exposure of cells to PC-TP inhibitors
resulted in dose-dependent, but insulin-independent activation of Akt, p70-S6K and GSK3β,
which are key effectors of insulin signaling (28). The relevance of these findings in vivo was
evidenced by increased basal levels of pAkt and p70-S6K in wild type, but not Pctp−/− mice
treated with compound A1. The possibility that compound A1 enhances insulin signaling is
consistent with our recent observations in HEK 293 cells following siRNA-mediated
knockdown of PC-TP (Ersoy et al., Hepatology 2010;52:591, abstract).
Metformin and thiazolidinediones are commonly utilized insulin sensitizing agents to
manage type 2 diabetes. The absence of consistent increases in phosphorylation of AMP-
activated protein kinase (AMPK) suggests a distinct activity of compound A1 from
metformin (29, 30). Compound A1 also failed to activate PPARγ, arguing against a
mechanism in common with thiazolidinediones (7, 31). In addition, the absence of ALT or
bilirubin elevations and lack of histologic evidence of liver damage or inflammation
indicated that chronic treatment of mice with compound A1 was not associated with
hepatotoxicity. The reductions in plasma bilirubin concentrations were observed in both
wild type and Pctp−/− mice, suggesting an additional off-target effect of compound A1.
Possible explanations include the induction of bilirubin metabolism or biliary secretion.
Because the objective in measuring plasma concentrations was to evaluate potential
hepatoxicity of compound A1, we have not yet pursued a mechanistic explanation in the
current study.
An important limitation of this study is that treatment with both compound A1 and vehicle
reduced weight gain together with fasting plasma glucose concentrations and degrees of
glucose intolerance in both genotypes when compared with untreated mice. Although likely
attributable to the frequency of i.p. injections performed during the 12 w treatment period, it
is possible that the vehicle, which contained 2-hydroxypropyl-β-cyclodextrin, did exert
metabolic effects. This could explain the noticeable difference in distribution of hepatic
lipids in treated mice, which exhibited microvesicular hepatic steatosis despite similar tissue
lipid concentrations as untreated mice in which we observed both macro- and microvesicular
distributions of hepatic fat. Appreciating that the administration of 2-hydroxypropyl-β-
cyclodextrin to mice can increase intracellular cholesterol transport (32), further study will
be required to ascertain the specific influence of the vehicle on hepatic lipid distribution. We
also noted tendencies toward increased hepatic and plasma concentrations of triglycerides
and cholesterol in both wild type and Pctp−/− mice treated with compound A1. The
occurrence of these changes independent of PC-TP expression is suggestive of an off-target
effect of the small molecule, the mechanism for which is not yet understood.
In summary, this study has served as proof of principle that genetic or chemical targeting of
PC-TP in a mouse model can attenuate diet-induced glucose intolerance by sensitizing the
liver to insulin action and reducing hepatic glucose production. If small molecule inhibitors
of PC-TP prove to be capable of treating established type 2 diabetes, they could represent a
novel approach to the management of this common disorder. Moreover, these compounds
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should be of value in efforts to dissect the molecular mechanisms by which PC-TP regulates
hepatic glucose metabolism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
List of Abbreviations
ALT alanine aminotransferase
AMPK AMP-activated protein kinase
AUC area under the curve
Clint intrinsic clearance
Cmax maximum plasma concentration
DHPE Lissamine rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine, triethylammonium salt
F fluorescence intensity
GSK3β glycogen synthase kinase 3β
HEK human embryonic kidney
Krel relative affinity
NEFA non-esterified fatty acids
NZO New Zealand Obese
NBD-PC 2-[12-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]dodecanoyl-1-hexadecanoyl-
sn-glycero-3 phosphocholine
PA phosphatidic acid
TCNQ 7,7,8,8-tetracyanoquinodimethane
PC-TP phosphatidylcholine transfer protein
PE phosphatidylethanolamine
PPARγ peroxisome proliferator-activated receptor γ
Pyr-PC 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphocholine
S6K p70 ribosomal S6 kinase
SM sphingomyelin
START steroidogenic acute regulatory protein-related transfer
Tm melting temperature
tmax time to maximum concentration
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Figure 1. Pctp−/− mice are resistant to diet-induced glucose intolerance
(A) Reduced fasting plasma glucose concentrations in mice lacking PC-TP. Wild type (n = 6
– 10) and Pctp−/− (n = 8 – 10) mice were fed a high fat (60% kcal) diet for up to 18 w.
Values for chow fed wild type and Pctp−/− mice of similar age to mice fed high fat for 8 w
are replotted from reference (6). (B) Decreased hepatic glucose production in Pctp−/− mice.
Values determined by hyperinsulinemic euglycemic clamp studies for wild type mice (n = 6)
and Pctp−/− mice (n = 8) fed the high fat diet for 18 w. (C) Pyruvate tolerance tests reflect
changes in hepatic glucose production. Wild type (n = 4) and Pctp−/− (n = 5) mice fed high
fat diet for 12 w were subjected to pyruvate tolerance tests. The barplot gives mean AUC
values. *P < 0.05 versus wild type mice.
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Figure 2. Structure-activity relationships of PC-TP inhibitors
Structures and inhibitory characteristics of small molecules derived from compounds A1 and
B1. “NA” denotes that a compound exhibited no activity, and “-” denotes that no
measurement was performed. Syntheses of small molecular inhibitors are illustrated in
Supporting Information.
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Figure 3. Compound A1 binds PC-TP, displaces phosphatidylcholine and increases thermal
stability
(A) Binding of compound A1 to PC-TP as assessed by surface plasmon resonance. Upper
panel: Compound A1 (50 – 100 µM) was injected for 150 s to allow binding and then
dissociation from PC-TP bound to a CM5 chip. Representative sensograms are shown
overlaid and zeroed on the y-axis to the average baseline before injection. The injection start
time for each sample was set to zero on the x-axis. Lower panel: Selected inhibitors were
analyzed by surface plasmon resonance. Rate constants of association (ka) and dissociation
(kd) were determined by non-linear least squares analysis of the sensogram data (SigmaPlot,
Systat Software, San Jose, CA) and used to calculate equilibrium dissociation constants, KD
= kd/ka. (B) Displacement of phosphatidylcholine from PC-TP by compound A1. Upper
panel: Emission scans of Pyr-PC in the absence of PC–TP or with PC–TP plus compound
A1. Lower panel: Relative affinity constants, Krel, were determined according to the
equation (33) ΔF(392 nM) = −1/Krel·([X]/[Pyr– PC])·ΔF(392 nM) + ΔFmax for X =
phosphatidylcholine or compound A1 by linear regression of ΔF plotted against the product
of ΔF(392 nM) and the molar ratio [X]/[Pyr-PC]. The inset bar plot displays values of Krel
(n = 3 – 4 determinations) for phosphatidylcholine and compound A1. *P = 0.0001. (C)
Stabilization of PC-TP by compound A1 using a thermal shift (ThermoFluor) assay.
Fluorescence intensity (upper panel) and first derivative, dF/dT of the melting curves (lower
panel) for PC–TP, PC–TP plus phosphatidylcholine and PC–TP with compound A1. Values
of Tm were determined using LightCycler Protein Melting software (Roche), which
identified Tm as minimum values of −dF/dT when plotted as functions of temperature. The
inset bar plot shows the comparison of the Tm values (n = 3 determinations) of PC–TP plus
phosphatidylcholine, and PC–TP plus compound A1. *P = 0.02.
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Figure 4. Compound A1 improves glucose homeostasis in high fat fed wild type but not Pctp−/−
mice
Improved glucose and pyruvate tolerance tests in wild type mice treated with compound A1.
High fat fed wild type mice and Pctp−/− mice were injected i.p. 5 d per w with 3 mg/kg of
compound A1 for 12 w. Mice were subjected to glucose tolerance tests (A: wild type -
vehicle n = 4, compound A1 n = 8; B: Pctp−/− - vehicle n = 3, compound A1 n = 4) and
pyruvate tolerance tests (C: wild type - vehicle n = 4, compound A1 n = 7; D: Pctp−/− -
vehicle n = 3, compound A1 n = 3). The inset bar plots provide AUC values for wild type
mice and Pctp−/− mice. *P < 0.05 versus vehicle treatment.
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Figure 5. Compound A1 enhances insulin signaling
(A) Compound A1 increases phosphorylation of selected mediators of insulin signaling in
cultured cells. Human hepatocytes (left panel) and HEK 293E cells (right panel) were serum
starved overnight, then treated with compound A1 for 1 h and harvested for immunoblot
analyses. Results are representative of 2 experiments for human hepatocytes and 3
experiments for HEK 293E cells. (B) Compound A1 increases phosphorylation of Akt and
S6K in livers of wild type mice. Homogenates of liver samples from mice fasted overnight
were subjected to immunoblotting and bands (Supporting Fig. 5B) were quantified by
densitometry. *P < 0.05 versus vehicle treatment.
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